Company intelligence / Profile preview

Altratech

Ownership: Private
Employees: ~20
Development stage: Preclinical

Overview

Altratech has developed a novel portable molecular diagnostics platform that combines silicon chip electronics with nanotechnology to enable rapid, multiplexed detection of DNA, RNA, antibodies, and antigens at the point-of-care or in home settings. The company’s first product aims to provide both viral load quantification and serology in a single device. Recent EIC Accelerator funding will support clinical trials in HIV diagnostics as well as expansion into broader infectious disease panels.

Therapeutic areas: Infectious Diseases
Modalities: DeviceDiagnostic platform (electronic molecular detection)Peptide nucleic acid probe-based assaySynthetic peptide nucleic acid (PNA) probesPeptide capture antigensCMOS semiconductor detector chip technology
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on Altratech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Altratech.

Explore the full profile